Drug Discovery Approaches for Epigenetic Targets

A growing understanding of the role of epigenetics in the aetiology of cancer and other diseases has
highlighted the potential for the development of newtherapies. To facilitate effective epigenetic drug
discovery programmes and address issues of compound promiscuity during early stages, Sygnature
Discovery has developed a range of complementary biochemical, biophysical, cellular target engagement
and biomarkermethodologies. In this poster, examples fromtwo different epigenetic projects
(Deubiquitinase (DUB) and Bromodomain targets) are presented.